A single index of primary material: the FAS decision, the commercial-court file, the official fine overview, the judicial timeline, evidence of business relationships and partners’ public compliance policies.
← Return to the investigationOfficial pages and documents open directly at the Russian FAS and the commercial-court case registry.
Unofficial translation; the Russian original is legally controlling.
The official Russian originals are the controlling texts. Other-language descriptions are editorial and do not replace a certified translation.
Commercial Court of the City of Moscow
Unofficial translation; the Russian original is legally controlling.Commercial Court of the City of Moscow
Unofficial translation; the Russian original is legally controlling.Commercial Court of the City of Moscow
Unofficial translation; the Russian original is legally controlling.Ninth Commercial Court of Appeal
Unofficial translation; the Russian original is legally controlling.Commercial Court of the City of Moscow
Unofficial translation; the Russian original is legally controlling.Ninth Commercial Court of Appeal
Unofficial translation; the Russian original is legally controlling.Ninth Commercial Court of Appeal
Unofficial translation; the Russian original is legally controlling.Ninth Commercial Court of Appeal
Unofficial translation; the Russian original is legally controlling.Federal Commercial Court of the Moscow District
Unofficial translation; the Russian original is legally controlling.Federal Commercial Court of the Moscow District
Unofficial translation; the Russian original is legally controlling.Federal Commercial Court of the Moscow District
Unofficial translation; the Russian original is legally controlling.Supreme Commercial Court of the Russian Federation
Unofficial translation; the Russian original is legally controlling.Supreme Commercial Court of the Russian Federation
Unofficial translation; the Russian original is legally controlling.Supreme Commercial Court of the Russian Federation
Unofficial translation; the Russian original is legally controlling.Supreme Commercial Court of the Russian Federation
Unofficial translation; the Russian original is legally controlling.Supreme Commercial Court of the Russian Federation
Unofficial translation; the Russian original is legally controlling.Supreme Commercial Court of the Russian Federation
Unofficial translation; the Russian original is legally controlling.Supreme Commercial Court of the Russian Federation
Unofficial translation; the Russian original is legally controlling.Commercial Court of the City of Moscow
Unofficial translation; the Russian original is legally controlling.Ninth Commercial Court of Appeal
Unofficial translation; the Russian original is legally controlling.Commercial Court of the City of Moscow
Unofficial translation; the Russian original is legally controlling.Commercial Court of the City of Moscow
Unofficial translation; the Russian original is legally controlling.Commercial Court of the City of Moscow
Unofficial translation; the Russian original is legally controlling.Ninth Commercial Court of Appeal
Unofficial translation; the Russian original is legally controlling.Commercial Court of the City of Moscow
Unofficial translation; the Russian original is legally controlling.Commercial Court of the City of Moscow
Unofficial translation; the Russian original is legally controlling.Ninth Commercial Court of Appeal
Unofficial translation; the Russian original is legally controlling.Ninth Commercial Court of Appeal
Unofficial translation; the Russian original is legally controlling.Federal Commercial Court of the Moscow District
Unofficial translation; the Russian original is legally controlling.Federal Commercial Court of the Moscow District
Unofficial translation; the Russian original is legally controlling.Federal Commercial Court of the Moscow District
Unofficial translation; the Russian original is legally controlling.Commercial Court of the City of Moscow
Unofficial translation; the Russian original is legally controlling.Commercial Court of the City of Moscow
Unofficial translation; the Russian original is legally controlling.Federal Commercial Court of the Moscow District
Unofficial translation; the Russian original is legally controlling.Ninth Commercial Court of Appeal
Unofficial translation; the Russian original is legally controlling.Ninth Commercial Court of Appeal
Unofficial translation; the Russian original is legally controlling.Ninth Commercial Court of Appeal
Unofficial translation; the Russian original is legally controlling.Federal Commercial Court of the Moscow District
Unofficial translation; the Russian original is legally controlling.Federal Commercial Court of the Moscow District
Unofficial translation; the Russian original is legally controlling.Federal Commercial Court of the Moscow District
Unofficial translation; the Russian original is legally controlling.Supreme Court of the Russian Federation
Unofficial translation; the Russian original is legally controlling.Supreme Court of the Russian Federation
Unofficial translation; the Russian original is legally controlling.Five key stages from the infringement decision to the end of the judicial chain.
FAS found ROSTA and Pharmstandard parties to a prohibited agreement in public procurement of medicines.
Pharmstandard received a turnover-based fine of RUB 201,381,295.10; FAS later reported more than RUB 402m combined for both participants.
The Moscow District commercial court set aside the initial judgments that had annulled the fine order.
On reconsideration in case No. A40-142261/2012, the application to annul the FAS fine order was dismissed.
The appellate and district cassation courts upheld the dismissal; Pharmstandard’s subsequent Supreme Court complaint did not alter the result.
For each international partner, the archive separately identifies the official website, public evidence of the relationship and the applicable policy or code.
In June 2025 Pharmstandard reported a GENERIUM–Sanofi agreement for full-cycle production of insulin glargine 300 U/ml. Sanofi separately publishes a commercial policy, updated on 23 January 2026, governing its agency agreement with Pharmstandard. This is the strongest public evidence of a continuing relationship.
Pharmstandard’s archive documents a strategic partnership and full-cycle localisation of Gazyva. Roche Moscow’s current page separately lists Pharmstandard as a distributor. Roche was not a party to the cartel case and is mentioned here only as a separate counterparty and the manufacturer of Pulmozyme.
Pharmstandard reports a 2013 agreement and localisation of secondary packaging for Synagis from 2014, and again names AbbVie as a partner in 2026. No independent public confirmation of the current product agreement was found.
The 2017 agreement covered technology transfer, manufacture, commercialisation and promotion of blinatumomab for seven years with an extension option. Pharmstandard names Amgen as a partner in 2026; Amgen has not published confirmation that this specific agreement was extended.
Pharmstandard names AstraZeneca on its current business-development page but discloses no subject, date or duration of an agreement. A joint 2024 compliance marathon does not itself prove a product contract; no independent confirmation of a current agreement was found.
Chiesi’s 2013 annual report confirms an agreement concerning Foster, while Pharmstandard includes Chiesi in its 2026 partner list. No public confirmation by Chiesi that the specific agreement continues in 2026 was found.
Eisai confirmed agreements to localise Halaven, Lenvima and Fycompa in 2016; Pharmstandard also names Eisai as a partner in 2026. The scope and continuation of the agreement at the current date are not publicly confirmed by the counterparty.
Pharmstandard reported a strategic partnership and full-cycle manufacture of Tractocile and Pabal at UfaVITA, and continues to name Ferring as a partner in 2026. No independent confirmation of the project’s current scope was found.
Pharmstandard’s archive records manufacturing and licensing arrangements for HIV, hepatitis C and COVID-19 medicines, including Sovaldi, Truvada, Epclusa, Biktarvy and Veklury. Gilead appears in the 2026 list, but the current scope of the agreements is not independently confirmed.
Both parties’ documents confirm licensing of Sirturo, technology transfer and contract manufacture for export; Velcade had been localised earlier. Pharmstandard names “Johnson, RUSSIA” in 2026, but J&J does not confirm the current status of the specific agreements.
J&J confirmed a memorandum and agreement to localise OneTouch test strips; Pharmstandard reported full transfer in 2020 and includes LifeScan Russia in its 2026 list. Since LifeScan became independent, no independent confirmation of the current relationship was found.
The agreements concerned manufacture, distribution and marketing of Rebif; an official Merck publication confirms local fill-and-finish. Pharmstandard names Merck Russia in 2026, but the project’s current status is not established. This is Germany’s Merck KGaA, not US-based MSD/Merck & Co.
Pharmstandard includes Novartis Pharma in its 2026 partner list. The archive records Tasigna sales but does not disclose an agreement, its date or scope; the counterparty has not confirmed a current relationship in the public materials reviewed.
The 2020 agreement covered technology transfer and contract manufacture of four oncology medicines; Pharmstandard published updates in 2023–2024 and names Pfizer in 2026. Pfizer’s adviser Clifford Chance independently confirms the transaction, but not its present performance.
Pharmstandard reports localisation and technology transfer for ADCETRIS and includes Takeda Russia in its 2026 list. Takeda is Japanese, not Western, and is shown separately for completeness of the official international list. The current scope is not independently confirmed.
Zentiva Pharma is named on Pharmstandard’s current partner page. The reviewed public record contains no disclosed subject, date or duration of an agreement and no independent confirmation by the counterparty.
Official reference pages for Russia, the European Union, the United Kingdom and the United States.
Article 11 of Law No. 135-FZ prohibits cartels; turnover-based administrative fines and, where the criminal elements are met, liability under Criminal Code article 178 may follow.
OpenArticle 101 TFEU prohibits cartels; a European Commission fine may reach 10% of the group’s total annual turnover.
OpenAlongside corporate sanctions, individuals may face the criminal cartel offence: up to five years’ imprisonment and an unlimited fine.
OpenAgreements among competitors to fix prices, allocate markets or rig bids are criminal Sherman Act violations, carrying major fines and imprisonment.
OpenBoundary of the conclusion: the historical infringement was established by FAS and judicially reviewed. It does not automatically prove a new infringement, Pharmstandard’s current motive or wrongdoing by its partners. Any new episode requires a separate investigation and evidence.